January 07, 2013 at 10:35 AM EST
Discovery Laboratories (DSCO) Begins Initial Phase of AFECTAIR Launch

QualityStocks would like to highlight Discovery Laboratories (NASDAQ: DSCO), a specialty biotechnology company focused on advancing a new standard in respiratory critical care through the development of novel technologies. The company is working to develop life-saving solutions that address persisting unmet medical needs in respiratory critical care. To do this, they are focused on two primary areas of development: their proprietary KL4 surfactant technology; and their novel drug delivery technologies to deliver aerosolized respiratory medicines, including their KL4 surfactant.

In the company’s news last week,

Discovery Laboratories announced that the launch of its AFECTAIR® airway connector has been initiated. The AFECTAIR® airway connector is designed for infants needing aerosolized medication in neonatal or pediatric intensive care units (NICU and PICU, respectively), and it simplifies medication delivery for those critical care patients who need ventilatory support. This simplification is provided through the innovative process of introducing the medication directly at the patient interface.

The initial phase of the launch is the introduction of an AFECTAIR user experience program in leading U.S. critical care centers, representing approximately ten percent of the company’s targeted institutions. The institutions chosen were selected based on their status as centers of influence within the neonatal and pediatric critical care community. The beginning of the launch is dedicated to facilitating peer-to-peer exchange that will enable discussion amongst physicians and respiratory therapists regarding the advantages and proper utilization of this cutting edge device. The opening phase of the launch is expected to close soon after the first quarter of 2013, at which time Discovery Labs will start a more expansive introduction of AFECTAIR.

“We are very excited to formally introduce AFECTAIR to the neonatal and pediatric critical care community,” said Thomas F. Miller, Chief Operating Officer at Discovery Labs. “The AFECTAIR technology exemplifies Discovery Labs’ innovative spirit and progress toward advancing new standards in respiratory critical care.”

The AFECTAIR technology was developed as a component of the AEROSURF® development program and is a proprietary, disposable device that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support such as intermittent mechanical ventilation or continuous positive airway pressure. To date, in vitro studies suggest that the AFECTAIR technology may be an effective new solution for delivering aerosolized medications to infants receiving ventilatory support while providing healthcare professionals with a simplified alternative to current practices. According to national health statistics and internal market assessment data, it is estimated that each year approximately 355,000 pediatric patients in the United States are eligible to receive aerosolized medications while requiring ventilator support.

Discovery Labs is also pursuing European Conformity (CE) marking for potential commercialization of AFECTAIR for infants in the European Union (EU) in 2013.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net 

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net  ;

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here